{"id":"tenidap","rwe":[{"pmid":"36082854","year":"2023","title":"Leprosy Reactions: Clinical Pharmacologist Perspective with Repurposed Medications.","finding":"","journal":"Infectious disorders drug targets","studyType":"Clinical Study"},{"pmid":"32832433","year":"2020","title":"What is New in the Pathogenesis and Management of Erythema Nodosum Leprosum.","finding":"","journal":"Indian dermatology online journal","studyType":"Clinical Study"},{"pmid":"32400832","year":"2020","title":"Acylation of oxindoles using methyl/phenyl esters via the mixed Claisen condensation - an access to 3-alkylideneoxindoles.","finding":"","journal":"Organic & biomolecular chemistry","studyType":"Clinical Study"},{"pmid":"31389319","year":"2019","title":"Activation of Kir2.3 Channels by Tenidap Suppresses Epileptiform Burst Discharges in Cultured Hippocampal Neurons.","finding":"","journal":"CNS & neurological disorders drug targets","studyType":"Clinical Study"},{"pmid":"31336325","year":"2019","title":"The anticonvulsant and neuroprotective effects of kir2.3 activation in PTZ-induced seizures and the kainic acid model of TLE.","finding":"","journal":"Epilepsy research","studyType":"Clinical Study"}],"tags":[{"label":"tenidap","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Prostaglandin G/H synthase 1","category":"target"},{"label":"PTGS1","category":"gene"},{"label":"PTGS2","category":"gene"},{"label":"KCNJ4","category":"gene"},{"label":"M01AX23","category":"atc"},{"label":"Active","category":"status"},{"label":"Rheumatoid arthritis","category":"indication"},{"label":"Analgesics","category":"pharmacology"},{"label":"Analgesics, Non-Narcotic","category":"pharmacology"},{"label":"Anti-Inflammatory Agents","category":"pharmacology"},{"label":"Anti-Inflammatory Agents, Non-Steroidal","category":"pharmacology"},{"label":"Antirheumatic Agents","category":"pharmacology"},{"label":"Cyclooxygenase Inhibitors","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Sensory System Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["tenidap sodium","tenidap"],"offLabel":[],"synonyms":["tenidap sodium","tenidap"],"timeline":[],"approvals":[],"ecosystem":[{"indication":"Rheumatoid arthritis","otherDrugs":[{"name":"abatacept","slug":"abatacept","company":"Bristol Myers Squibb"},{"name":"aceclofenac","slug":"aceclofenac","company":""},{"name":"acetylsalicylic acid","slug":"acetylsalicylic-acid","company":"Endo Pharms"},{"name":"adalimumab","slug":"adalimumab","company":"Abbvie Inc"}],"globalPrevalence":18000000}],"mechanism":{"target":"Prostaglandin G/H synthase 1","targets":[{"gene":"PTGS1","source":"DrugCentral","target":"Prostaglandin G/H synthase 1","protein":"Prostaglandin G/H synthase 1"},{"gene":"PTGS2","source":"DrugCentral","target":"Prostaglandin G/H synthase 2","protein":"Prostaglandin G/H synthase 2"},{"gene":"KCNJ4","source":"DrugCentral","target":"Inward rectifier potassium channel 4","protein":"Inward rectifier potassium channel 4"},{"gene":"CYP2C9","source":"DrugCentral","target":"Cytochrome P450 2C9","protein":"Cytochrome P450 2C9"},{"gene":"CYP1A2","source":"DrugCentral","target":"Cytochrome P450 1A2","protein":"Cytochrome P450 1A2"}],"modality":"Small Molecule","drugClass":"tenidap","explanation":"Think of it like a fire alarm in a building. When there's an injury or infection, the body sends out chemical signals to alert the immune system to respond. TENIDAP helps to silence this alarm by blocking the production of these chemical signals, which reduces inflammation and pain.","oneSentence":"TENIDAP works by inhibiting the enzyme Prostaglandin G/H synthase 1, which plays a key role in the production of inflammatory mediators.","technicalDetail":"TENIDAP specifically inhibits the cyclooxygenase (COX) enzyme, which is responsible for converting arachidonic acid into prostaglandins and thromboxanes, key mediators of inflammation and pain."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4728","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=TENIDAP","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:50:03.310061","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:51:17.010959+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"nabumetone","drugSlug":"nabumetone","fdaApproval":"1991-12-24","genericCount":14,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"glucosamine","drugSlug":"glucosamine","fdaApproval":"","relationship":"same-class"},{"drugName":"orgotein","drugSlug":"orgotein","fdaApproval":"","relationship":"same-class"}],"genericName":"tenidap","indications":{"approved":[{"name":"Rheumatoid arthritis","source":"DrugCentral","snomedId":69896004,"regulator":"FDA","usPrevalence":1500000,"globalPrevalence":18000000,"prevalenceMethod":"curated","prevalenceSource":"Lancet Rheumatology, 2023"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"nabumetone","brandName":"nabumetone","genericName":"nabumetone","approvalYear":"1991","relationship":"same-class"},{"drugId":"glucosamine","brandName":"glucosamine","genericName":"glucosamine","approvalYear":"","relationship":"same-class"},{"drugId":"orgotein","brandName":"orgotein","genericName":"orgotein","approvalYear":"","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"008173","UNII":"9K7CJ74ONH","CHEBI":"CHEBI:35847","INN_ID":"6421","UMLSCUI":"C0076092","ChEMBL_ID":"CHEMBL1908355","KEGG_DRUG":"D06072","DRUGBANK_ID":"DB13481","PDB_CHEM_ID":" I2U","PUBCHEM_CID":"60712","IUPHAR_LIGAND_ID":"2395","SECONDARY_CAS_RN":"119784-94-0","MESH_SUPPLEMENTAL_RECORD_UI":"C062866"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"22.7 hours","clearance":"0.058 mL/min/kg","fractionUnbound":"0.01%","volumeOfDistribution":"0.11 L/kg"},"publicationCount":0,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"M01AX23","allCodes":["M01AX23"]},"biosimilarFilings":[],"recentPublications":[{"date":"2023","pmid":"36082854","title":"Leprosy Reactions: Clinical Pharmacologist Perspective with Repurposed Medications.","journal":"Infectious disorders drug targets"},{"date":"2020 Jul-Aug","pmid":"32832433","title":"What is New in the Pathogenesis and Management of Erythema Nodosum Leprosum.","journal":"Indian dermatology online journal"},{"date":"2020 May 27","pmid":"32400832","title":"Acylation of oxindoles using methyl/phenyl esters via the mixed Claisen condensation - an access to 3-alkylideneoxindoles.","journal":"Organic & biomolecular chemistry"},{"date":"2019","pmid":"31389319","title":"Activation of Kir2.3 Channels by Tenidap Suppresses Epileptiform Burst Discharges in Cultured Hippocampal Neurons.","journal":"CNS & neurological disorders drug targets"},{"date":"2019 Oct","pmid":"31336325","title":"The anticonvulsant and neuroprotective effects of kir2.3 activation in PTZ-induced seizures and the kainic acid model of TLE.","journal":"Epilepsy research"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"TENIDAP","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TENIDAP is a small molecule. It is also known by the synonyms CP-66,248 and CP-66248.","enrichmentLevel":5,"visitCount":0,"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T08:51:17.010959+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":false,"score":2}}